Most Clicked DiabetesPro SmartBrief Stories


1. Research explains how inflammation affects diabetes

DiabetesPro SmartBrief | Sep 12, 2014

Data presented at an American Heart Association meeting revealed glucose did not enter cultured aortic cells without the presence of inflammation, and the cells did not show damage even when glucose was forced into them. However, adding the inflammatory protein interleukin-1 prompted the cells to metabolize glucose and spurred an inflammation cycle. The results suggest that glucose control may not be sufficient to stave off cardiovascular disease risk in diabetes and that anti-inflammatory drugs and lifestyle modification may help stem the risk. Time.com (09/11)


2. Lower diabetes odds seen with high-fat dairy consumption

DiabetesPro SmartBrief | Sep 16, 2014

Participants who had the highest consumption of high-fat dairy products had a 23% lower risk of type 2 diabetes than did those with the lowest intake, researchers reported at the European Association for the Study of Diabetes meeting. Research also showed that eating both low-fat and high-fat meat was linked to an increased risk of diabetes. MedicalDaily.com (09/15)


3. Better diabetes outcomes seen with insulin plus GLP-1

DiabetesPro SmartBrief | Sep 15, 2014

An analysis in The Lancet revealed a combination of insulin and glucagon-like peptide-1 agonist was 92% more effective than standard diabetes treatments in boosting blood glucose control in diabetes patients. Data also showed the combination treatment carried no greater risk of low blood glucose and was tied to an average weight loss of 7 pounds. HealthDay News (09/12)


4. Data show age, diabetes duration tied to macrovascular risks

DiabetesPro SmartBrief | Sep 15, 2014

Research published in Diabetologia showed diabetes patients in the oldest age group with the longest disease duration had a significantly increased odds of macrovascular events and mortality. The risk of microvascular events correlated with diabetes duration but were reduced with age, with the greater risks seen among younger patients with the longest diabetes duration. Healio (free registration) (09/12)


5. A1C threshold may predict gestational diabetes

DiabetesPro SmartBrief | Sep 16, 2014

A study in Diabetes Care found an A1C threshold of ≥5.9% during early pregnancy showed a 98.4% specificity in detecting gestational diabetes. Researchers also noted poorer pregnancy outcomes in patients with an A1C of 5.9% to 6.4% compared with those who had lower rates. PhysiciansBriefing.com (09/15)


6. Old insulin comes with hefty new price tag

DiabetesPro SmartBrief | Sep 15, 2014

The concentrated U-500 formulation of insulin first hit the market in 1952, and today's formulation generated using recombinant DNA technology became available in 1997. Demand for U-500 has risen along with obesity and diabetes rates, and the wholesale price for a one-month supply has risen from $220 in 2007 to $1,200 this year. MedPage Today (free registration) (09/12)


7. Technique rapidly converts stem cells to insulin-producing cells

DiabetesPro SmartBrief | Sep 16, 2014

Researchers at the University of British Columbia in Canada have discovered a way to speed up the conversion of stem cells into insulin-producing cells, a step that could lead to transplants that treat type 1 diabetes. The technique can create insulin-producing cells in about six weeks, according to the study in the journal Nature Biotechnology. Business Standard (India) (09/12)


8. South Asians exhibit lower insulin sensitivity

DiabetesPro SmartBrief | Sep 17, 2014

South Asians showed significantly lower insulin sensitivity for as long as 15 years prior to type 2 diabetes diagnosis compared with their white counterparts, according to research presented at the European Association for the Study of Diabetes meeting. Data also showed South Asians had greater fasting plasma glucose rates at diagnosis than whites. MedPage Today (free registration) (09/16)


9. FDA panel backs liraglutide for obese patients

DiabetesPro SmartBrief | Sep 12, 2014

An FDA advisory panel on Thursday voted 14 to 1 to recommend Novo Nordisk's drug liraglutide for chronically obese patients with at least one weight-related disorder. The drug is to be sold under the brand name Saxenda if approved. Reuters (09/11)


10. Free CME/CE Opportunity: Hypoglycemia and Diabetes

DiabetesPro SmartBrief | Sep 12, 2014

This self-assessment program consists of clinical problem-solving multiple choice questions and educational critiques. It is designed to objectively assess and strengthen your knowledge of diabetes and provide you with a better understanding of working with patients with type 2 diabetes. Content was developed based on the 2013 scientific statement on the same subject issued by the ADA and TES. Earn up to 3.75 continuing education credits. Learn more. Blank (12/16)




Sign up for DiabetesPro SmartBrief



Designed specifically for health care professionals, DiabetesPro SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news, trends, and technology updates that matter most to health care professionals. Learn more